Aktuelle smitsomme sygdomme
Søgeord (covid) valgt.
110 emner vises.
Joseph Meletiadis, Maria Siopi, Bram Spruijtenburg, Panagiota-Christina Georgiou, Maria Kostoula, Sophia Vourli, Frantzeska Frantzeskaki , Elisabeth Paramythiotou, Jacques F Meis, Iraklis Tsangaris and Spyros Pournaras
Eurosurveillance latest updates, 8.11.2024
Tilføjet 8.11.2024
After the start of the COVID-19 pandemic, a rapid rise in reported numbers and wide geographic spread of Candida auris-related invasive infections has been observed globally. However, the contemporary epidemiology of C. auris fungaemias in Greece remains unknown. An outbreak of C. auris bloodstream infections has been ongoing for almost 3 years in a Greek tertiary care academic hospital, with 89 C. auris-driven episodes appearing in five waves every 6–7 months following peaks in colonisation rates by 3–4 months. All isolates clustered in clade I and were genetically related, 84% were fluconazole-resistant and all were non-resistant to amphotericin B and echinocandins, except one pan-echinocandin-resistant isolate (FKS1S639F mutant) recovered from a patient on empiric therapy with anidulafungin. Notably, C. auris was in 2023 the most prevalent (34%) cause of candidaemia in our hospital. The accelerated and long-term transmission dynamics of C. auris fungaemia underscore the need for rigorous infection control measures, while antifungal stewardship is warranted to contain the selection of echinocandin-resistant isolates.
Læs mereMarco Del Riccio, Marta C Nunes, Benjamin J Cowling, Bruno Lina, John W McCauley, Adam Meijer , Hanna Nohynek, Bronke Boudewijns and Saverio Caini
Eurosurveillance latest updates, 8.11.2024
Tilføjet 8.11.2024
The COVID-19 pandemic and related preventive measures reduced influenza virus circulation, notably causing the disappearance of the B/Yamagata lineage of influenza viruses. In this Perspective, we discuss the implications that this development may have for global influenza epidemiology, and the adjustments that may need to be implemented concerning surveillance strategies and practices, laboratory safety protocols, and influenza vaccine formulations. The disappearance of the B/Yamagata lineage might indeed alter the dynamics of the influenza disease burden (although in a way that is difficult to predict at the moment), and associated diagnostic practices, and may also necessitate updated biosafety levels and revised influenza surveillance strategies. Furthermore, the World Health Organization (WHO) recommended in September 2023 the exclusion of B/Yamagata antigens from future vaccines, with a shift towards trivalent vaccines or modified quadrivalent vaccines; this new scenario underscores the importance of robust global respiratory virus surveillance, effective communication with healthcare professionals and the population to maintain trust in vaccines, and a collaborative approach among health policymakers and vaccine manufacturers to navigate this epidemiological change.
Læs mereMary A Sinnathamby, Tania Bourouphael, Jacob Boateng, Magali Collonnaz, Catherine Quinot, Nurin Abdul Aziz, Suzanne Elgohari, Rebecca E Green, Gavin Dabrera, Jamie Lopez-Bernal and Alex Allen
Eurosurveillance latest updates, 8.11.2024
Tilføjet 8.11.2024
We developed a new activity level setting threshold method, the mean standard deviation (MSD) method to quantify COVID-19 activity levels. This has been validated against the moving epidemic method (MEM), which has been used for influenza for many years, and we observed very similar results. The MSD method can prove to be a tool to use for respiratory viruses with limited historical data or seasonality to quantify activity levels when other respiratory viruses are also circulating.
Læs mereMedscape Infectious Diseases, 2.11.2024
Tilføjet 2.11.2024
SARS-CoV-2 burden on the floor was linked to outbreaks in two acute care hospitals, suggesting that floor sampling could play a role in localized surveillance of the virus. Medscape Medical News
Læs mereCamelia Savulescu, Albert Prats-Uribe, Kim Brolin, Anneli Uusküla, Colm Bergin, Catherine Fleming, Rita Murri, Viesturs Zvirbulis, Dace Zavadska, Vania Gaio, Corneliu P Popescu, Raluca Hrisca, Maria Cisneros, Miriam Latorre-Millán, Liis Lohur, Jonathan McGrath, Lauren Ferguson, Katleen De Gaetano Donati, Ilze Abolina, Dagne Gravele, Ausenda Machado, Simin-Aysel Florescu, Mihaela Lazar, Pilar Subirats, Laura Clusa Cuesta, Jacklyn Sui, Claire Kenny, Rosaria Santangelo, Dainis Krievins, Elza Anna Barzdina, Camila Valadas Henriques, Alma Gabriela Kosa, Saftica-Mariana Pohrib, Carmen Muñoz-Almagro, Ana Milagro, Sabrina Bacci, Anthony Nardone and VEBIS HCW VE study group
Eurosurveillance latest updates, 1.11.2024
Tilføjet 1.11.2024
COVID-19 vaccination recommendations include healthcare workers (HCWs). We measured COVID-19 vaccine effectiveness (CVE) of the autumn 2023 dose against laboratory-confirmed SARS-CoV-2 infection in a prospective cohort study of 1,305 HCWs from 13 European hospitals. Overall CVE was 22% (95% CI: −17 to 48), 49% (95% CI: −8 to 76) before and −11% (95% CI: −84 to 34) after the start of BA.2.86/JN.1 predominant circulation. Autumn 2023 COVID-19 vaccination led to a moderate-to-low reduction in SARS-CoV-2 infection incidence in HCWs. Monitoring of CVE is crucial for COVID-19 prevention.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 1.11.2024
Tilføjet 1.11.2024
This report describes influenza vaccination and COVID-19 vaccination coverage among health care personnel during the 2023-24 respiratory virus season (October 1, 2023-March 31, 2024).
Læs mereMedscape Infectious Diseases, 31.10.2024
Tilføjet 31.10.2024
Building trust over time and reducing practical barriers for vaccines may increase uptake. Medscape Medical News
Læs mereMedscape Infectious Diseases, 31.10.2024
Tilføjet 31.10.2024
Policy, funding, and public apathy hold back the search for more advanced COVID vaccines — but researchers persist and have made headway. Medscape Medical News
Læs mereMedscape Infectious Diseases, 31.10.2024
Tilføjet 31.10.2024
Tuberculosis replaced COVID-19 to become the top cause for infectious disease-related deaths in 2023, according to a World Health Organization report published on Tuesday,... Reuters Health Information
Læs mereMedscape Infectious Diseases, 30.10.2024
Tilføjet 30.10.2024
Using COVID-19 vaccine technology, researchers created an mRNA vaccine targeting C difficile, showing strong immune responses in animal studies. Medscape Medical News
Læs mereMedscape Infectious Diseases, 30.10.2024
Tilføjet 30.10.2024
Japan\'s Shionogi & Co said on Tuesday a global, late-stage study showed its pill-based treatment for COVID-19 was effective in reducing transmission of the... Reuters Health Information
Læs mereECDC
ECDC COVID-19 updates, 29.10.2024
Tilføjet 29.10.2024
Seasonal influenza and COVID-19 vaccination uptake for risk groups such as the elderly were sub-optimal in several EU/EEA Member States during the 2023-2024 season, according to two reports released today by the European Centre for Disease Prevention and Control (ECDC).
Læs mereECDC
ECDC COVID-19 updates, 29.10.2024
Tilføjet 29.10.2024
This report presents a description of COVID-19 vaccine coverage in the European Union/European Economic Area (EU/EEA) between 1 September 2023 and 31 July 2024.
Læs mereJantien A Backer, Eric R A Vos, Gerco den Hartog, Cheyenne C E van Hagen, Hester E de Melker, Fiona R M van der Klis and Jacco Wallinga
Eurosurveillance latest updates, 26.10.2024
Tilføjet 26.10.2024
BackgroundThe first wave of the COVID-19 pandemic in 2020 was largely mitigated by limiting contacts in the general population. In early 2022, most contact-reducing measures were lifted. AimTo assess whether the population has reverted to pre-pandemic contact behaviour and how this would affect transmission potential of a newly emerging pathogen. MethodsWe compared two studies on contact behaviour in the Netherlands: the PIENTER Corona study, conducted during and after the pandemic (held every 2–6 months from April 2020) and the PIENTER3 study (2016–17, as pre-pandemic baseline). In both, participants (ages 1–85 years) reported number and age group of all face-to-face persons contacted on the previous day in a survey. Transmission potential was examined using the next-generation matrix approach. ResultsWe found an average of 15.4 (95% CI: 14.3–16.4) community contacts per person per day after the pandemic in May 2023, 13% lower than baseline (17.8; 95% CI: 17.0–18.5). Among all ages, children (5–9 years) had the highest number of contacts, both pre- and post-pandemic. Mainly adults aged 20–59 years had not reverted to pre-pandemic behaviours, possibly because they more often work from home. Although the number of contacts is lower compared to the pre-pandemic period, the effect on transmission potential of a newly emerging respiratory pathogen is limited if all age groups were equally susceptible. ConclusionContinuous monitoring of contacts can signal changes in contact patterns and can define a ‘new normal’ baseline. Both aspects are needed to prepare for a future pandemic.
Læs mereMedscape Infectious Diseases, 24.10.2024
Tilføjet 24.10.2024
Ethicist Art Caplan discusses board decertification of doctors for spreading misinformation about ivermectin during the COVID-19 pandemic. Medscape Business of Medicine
Læs mereMedscape Infectious Diseases, 23.10.2024
Tilføjet 23.10.2024
When it was prescribed within a week of SARS CoV-2 infection, metformin was associated with a 53% reduction in long COVID or death. Medscape Medical News
Læs mereMedscape Infectious Diseases, 21.10.2024
Tilføjet 21.10.2024
Economic estimates are rising as more long COVID case data become clear. Experts weigh the fixes. Medscape Medical News
Læs mereMedscape Infectious Diseases, 19.10.2024
Tilføjet 19.10.2024
Europe’s drug regulator recommended two novel vaccines for influenza alongside updated composition for two COVID-19 vaccines previously approved by the EC. Medscape Medical News
Læs mereErik Lundgren, Macauley Locke, Ethan Romero-Severson, Mira Dimitrijevic, Maria Axelsson, Emmi Andersson, Christina Carlander, Johanna Brännström, Hans Norrgren, Fredrik Mansson, Olof Elvstam, Magnus Gisslén, Lisa Fohlin, Anders Sönnerborg, Jan Albert and Thomas Leitner
Eurosurveillance latest updates, 18.10.2024
Tilføjet 18.10.2024
BackgroundSweden reached the UNAIDS 90–90–90 target in 2015. It is important to reassess the HIV epidemiological situation due to ever-changing migration patterns, the roll-out of PrEP and the impact of the COVID-19 pandemic. AimWe aimed to assess the progress towards the UNAIDS 95–95–95 targets in Sweden by estimating the proportion of undiagnosed people with HIV (PWHIV) and HIV incidence trends. MethodsWe used routine laboratory data to inform a biomarker model of time since infection. When available, we used previous negative test dates, arrival dates for PWHIV from abroad and transmission modes to inform our incidence model. We also used data collected from the Swedish InfCareHIV register on antiretroviral therapy (ART). ResultsThe yearly incidence of HIV in Sweden decreased after 2014. In part, this was because the fraction of undiagnosed PWHIV had decreased almost twofold since 2006. After 2015, three of four PWHIV in Sweden were diagnosed within 1.9 and 3.2 years after infection among men who have sex with men and in heterosexual groups, respectively. While 80% of new PWHIV in Sweden acquired HIV before immigration, they make up 50% of the current PWHIV in Sweden. By 2022, 96% of all PWHIV in Sweden had been diagnosed, and 99% of them were on ART, with 98% virally suppressed. ConclusionsBy 2022, about half of all PWHIV in Sweden acquired HIV abroad. Using our new biomarker model, we assess that Sweden has reached the UNAIDS goal at 96–99–98.
Læs mereMedscape Infectious Diseases, 17.10.2024
Tilføjet 17.10.2024
In a prospective cohort study, in utero exposure to COVID-19 was not associated with abnormal neurodevelopment in children up to 2 years of age. Medscape Medical News
Læs mereMedscape Infectious Diseases, 17.10.2024
Tilføjet 17.10.2024
The U.S. Food and Drug Administration has put on hold a trial of Novavax\'s COVID-influenza and its standalone flu vaccines after a participant who took the combination shot... Reuters Health Information
Læs mereMedscape Infectious Diseases, 16.10.2024
Tilføjet 16.10.2024
1.4 million. That’s the tally of excess deaths during the COVID pandemic in the United States. But it turns out that the pain of those losses was not spread evenly throughout society. Medscape
Læs mereMedscape Infectious Diseases, 14.10.2024
Tilføjet 14.10.2024
New data: Researchers cautioned those with previous CVD have a higher risk of developing long COVID and should take steps to avoid infection. Medscape Medical News
Læs mereMedscape Infectious Diseases, 11.10.2024
Tilføjet 11.10.2024
Study shows COVID-19 was associated with higher self-reported incidence of fatigue and other symptoms. Medscape Medical News
Læs mereKevin A Brown, Sarah A Buchan, Adrienne K Chan, Andrew Costa, Nick Daneman, Gary Garber, Michael Hillmer, Aaron Jones, James M Johnson, Dylan Kain, Kamil Malikov, Richard G Mather, Allison McGeer, Kevin L Schwartz, Nathan M Stall and Jennie Johnstone
Eurosurveillance latest updates, 11.10.2024
Tilføjet 11.10.2024
BackgroundLate outbreak identification is a common risk factor mentioned in case reports of large respiratory infection outbreaks in long-term care (LTC) homes. AimTo systematically measure the association between late SARS-CoV-2 outbreak identification and secondary SARS-CoV-2 infection and mortality in residents of LTC homes. MethodsWe studied SARS-CoV-2 outbreaks across LTC homes in Ontario, Canada from March to November 2020, before the COVID-19 vaccine rollout. Our exposure (late outbreak identification) was based on cumulative infection pressure (the number of infectious resident-days) on the outbreak identification date (early: ≤ 2 infectious resident-days, late: ≥ 3 infectious resident-days), where the infectious window was −2 to +8 days around onset. Our outcome consisted of 30-day incidence of secondary infection and mortality, based on the proportion of at-risk residents with a laboratory-confirmed SARS-CoV-2 infection with onset within 30 days of the outbreak identification date. ResultsWe identified 632 SARS-CoV-2 outbreaks across 623 LTC homes. Of these, 36.4% (230/632) outbreaks were identified late. Outbreaks identified late had more secondary infections (10.3%; 4,437/42,953) and higher mortality (3.2%; 1,374/42,953) compared with outbreaks identified early (infections: 3.3%; 2,015/61,714; p
Læs mereRobert Dyrdak, Emma B Hodcroft, Sandra Broddesson, Malin Grabbe, Hildur Franklin, Magnus Gisslén, Maricris E Holm, Magnus Lindh, Joanna Nederby-Öhd, Johan Ringlander, Martin Sundqvist, Richard A Neher and Jan Albert
Eurosurveillance latest updates, 11.10.2024
Tilføjet 11.10.2024
BackgroundDespite the unprecedented measures implemented globally in early 2020 to prevent the spread of SARS-CoV-2, Sweden, as many other countries, experienced a severe first wave during the COVID-19 pandemic. AimWe investigated the introduction and spread of SARS-CoV-2 into Sweden. MethodsWe analysed stored respiratory specimens (n = 1,979), sampled 7 February–2 April 2020, by PCR for SARS-CoV-2 and sequenced PCR-positive specimens. Sequences generated from newly detected cases and stored positive specimens February–June 2020 (n = 954) were combined with sequences (Sweden: n = 730; other countries: n = 129,913) retrieved from other sources for Nextstrain clade assignment and phylogenetic analyses. ResultsTwelve previously unrecognised SARS-CoV-2 cases were identified: the earliest was sampled on 3 March, 1 week before recognised community transmission. We showed an early influx of clades 20A and 20B from Italy (201/328, 61% of cases exposed abroad) and clades 19A and 20C from Austria (61/328, 19%). Clade 20C dominated the first wave (20C: 908/1,684, 54%; 20B: 438/1,684, 26%; 20A: 263/1,684, 16%), and 800 of 1,684 (48%) Swedish sequences formed a country-specific 20C cluster defined by a spike mutation (G24368T). At the regional level, the proportion of clade 20C sequences correlated with an earlier weighted mean date of COVID-19 deaths. ConclusionCommunity transmission in Sweden started when mitigation efforts still focused on preventing influx. This created a transmission advantage for clade 20C, likely introduced from ongoing cryptic spread in Austria. Therefore, pandemic preparedness should have a comprehensive approach, including capacity for large-scale diagnostics to allow early detection of travel-related cases and community transmission.
Læs mereLuisa K Hallmaier-Wacker, Merel D van Eick, Olivier Briët, Hugues Delamare, Gerhard Falkenhorst, Sandrine Houzé, Harold Noël, Javiera Rebolledo, Wim Van Bortel and Céline M Gossner
Eurosurveillance latest updates, 11.10.2024
Tilføjet 11.10.2024
BackgroundAirport and luggage (also called Odyssean) malaria are chance events where Plasmodium infection results from the bite of an infected mosquito which was transported by aircraft from a malaria-endemic area. Infrequent case reports and a lack of central data collection challenge a comprehensive overview. AimTo update the epidemiological, clinical and biological understanding of airport and luggage malaria cases in Europe. MethodsWe conducted a systematic review of studies indexed from 1969 to January 2024 in MEDLINE, Embase and OpenGrey databases. A data call to EU/EEA and UK public health institutes was launched in December 2022. ResultsOf the 145 cases (89 cases from 48 studies and 56 cases from the data call) described from nine countries, 105 were classified as airport malaria, 32 as luggage malaria and eight as either airport or luggage malaria. Most airport malaria cases were reported in France (n = 52), Belgium (n = 19) and Germany (n = 9). Half of cases resided or worked near or at an international airport (mean distance of 4.3 km, n = 28). Despite disruptions in air travel amid the COVID-19 pandemic, one third of cases reported since 2000 occurred between 2018 and 2022, with a peak in 2019. ConclusionWhile airport and luggage malaria cases are rare, reports in Europe have increased, highlighting the need for effective prevention measures and a more structured surveillance of cases in Europe. Prevention measures already in place such as aircraft disinsection should be assessed for compliance and effectiveness.
Læs mereECDC
ECDC COVID-19 updates, 11.10.2024
Tilføjet 11.10.2024
This focused after-action review (AAR) investigated the use of evidence in the Finnish advice-making process for school interventions from December 2021 to January 2022, when the SARS-CoV-2 Omicron variant was circulating and schools remained open.
Læs mereStatens Serum Institut, 11.10.2024
Tilføjet 11.10.2024
Statens Serum Institut, 10.10.2024
Tilføjet 10.10.2024
Udmattelse som senfølge efter smitte med covid-19 er mindre udbredt end frygtet, viser nyt studie fra Statens Serum Institut. Udviklingen ses især efter, at vaccinationerne blev indført, og at omikron-varianten blev den fremherskende covid-19-variant.
Læs mereMedscape Infectious Diseases, 8.10.2024
Tilføjet 8.10.2024
Nearly 90% of babies who had to be hospitalized with COVID-19 had mothers who didn\'t get the vaccine while they were pregnant. KFF Health News
Læs mereBrechje de Gier, Jan van de Kassteele, Liselotte van Asten, Annelot F Schoffelen, ISIS-AR study group, Mariette Hooiveld, Margreet JM te Wierik, Nina M van Sorge and Hester E de Melker
Eurosurveillance latest updates, 5.10.2024
Tilføjet 5.10.2024
BackgroundAfter most COVID-19 pandemic control measures were lifted in 2022, many infectious diseases re-emerged. An increase in invasive group A streptococcal (iGAS) infections among adults and young children was reported by several countries. Viral infections including influenza and varicella, known risk factors for iGAS infection, also increased. AimTo estimate the proportion of GAS skin and soft tissue infections (SSTI) and pneumonia/sepsis in children (≤ 5 years) attributable to varicella, and the proportion of GAS pneumonia/sepsis in children and adults attributable to potentially predisposing respiratory viruses influenza A and B, RSV, hMPV and SARS-CoV-2 in the Netherlands. MethodsWe performed time series regression using weekly data on respiratory viruses, varicella and non-invasive GAS infections and GAS isolates cultured from blood, lower airways, skin, pus and wounds, from January 2010 to March 2023. ResultsIn 2010–19, 50% (95% CI: 36–64) of GAS SSTI in children were attributable to varicella. Between January 2022 and March 2023, 34% (95% CI: 24–43) of GAS SSTI cases were attributable to varicella. Of iGAS pneumonia/sepsis between January 2022 and March 2023, 34% (95% CI: 20–49) and 25% (95% CI: 18–32) was attributable to respiratory virus infections in children and adults, respectively, with the largest contributor (17%) being influenza A. ConclusionsPredisposing viral infections likely contributed to, but cannot fully explain, the observed iGAS increase among children and adults in 2022–23 in the Netherlands. Public health measures to control viral infections, such as vaccination against varicella or influenza, might reduce the iGAS disease burden.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 4.10.2024
Tilføjet 4.10.2024
This report describes the percentage of older adults with a COVID-19 diagnosis who received a recommended COVID-19 antiviral medication.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 4.10.2024
Tilføjet 4.10.2024
Medscape Infectious Diseases, 4.10.2024
Tilføjet 4.10.2024
Europe has announced a €2 million project to research long COVID, following €100 million already invested since 2021. Is all this money bringing new insights? Medscape Medical News
Læs mereMedscape Infectious Diseases, 3.10.2024
Tilføjet 3.10.2024
Fresh data show that long COVID in children is more common than previously thought, while symptoms — particularly gastrointestinal — can differ from adults\'. Medscape Medical News
Læs mereMedscape Infectious Diseases, 3.10.2024
Tilføjet 3.10.2024
Physicians detail their predictions on the upcoming COVID-19 and flu season, sharing recommendations to increase patient awareness and advise on vaccinations. WebMD Health News
Læs mereMedscape Infectious Diseases, 2.10.2024
Tilføjet 2.10.2024
The COVID-19 pandemic highlighted the urgent need to modernize public health data systems. Health providers play a key role, says CDC\'s Dr. Jennifer Layden. CDC Expert Commentary
Læs mereStatens Serum Institut, 1.10.2024
Tilføjet 1.10.2024
Statens Serum Institut påviser, at covid-19 har været forbundet med mere end dobbelt så mange indlæggelser og dødsfald set i forhold til influenza.
Læs mereMedscape Infectious Diseases, 28.09.2024
Tilføjet 28.09.2024
A new study hints at a possible connection between infections and unexplained infant deaths. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 27.09.2024
Tilføjet 27.09.2024
Medscape Infectious Diseases, 27.09.2024
Tilføjet 27.09.2024
Recently analyzed data point to masked palm civets and civets at the Huanan market in Wuhan. Medscape Medical News
Læs mereMedscape Infectious Diseases, 26.09.2024
Tilføjet 26.09.2024
A new COVID-19 variant called XEC is on the rise, and it has experts who track variants on alert. WebMD Health News
Læs mereMedscape Infectious Diseases, 21.09.2024
Tilføjet 21.09.2024
The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two COVID-19 vaccines. Medscape Medical News
Læs mereStatens Serum Institut, 20.09.2024
Tilføjet 20.09.2024
Repræsentanter fra 22 lande i Europa samt ECDC og WHO mødes i denne uge i København til en 3-dages workshop for at udveksle erfaringer og diskutere nye metoder og muligheder til overvågning af overdødelighed under epidemier som covid-19 og influenza.
Læs mereECDC
ECDC COVID-19 updates, 18.09.2024
Tilføjet 18.09.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mereMedscape Infectious Diseases, 17.09.2024
Tilføjet 17.09.2024
The use of antipsychotics for schizophrenia was associated with higher risk for severe cases of COVID-19 and non–COVID-19 respiratory infections but not mild infection. Medscape Medical News
Læs mereMedscape Infectious Diseases, 16.09.2024
Tilføjet 16.09.2024
A study found abnormal lung perfusion in long-COVID patients with normal CT scans, highlighting pulmonary vascular issues. At ERS 2024, researchers call for further investigation into the condition. Medscape Medical News
Læs mereEero Poukka, Jori Perälä, Hanna Nohynek, Sirkka Goebeler, Kari Auranen, Tuija Leino and Ulrike Baum
Eurosurveillance latest updates, 13.09.2024
Tilføjet 13.09.2024
BackgroundLong-term effectiveness data on bivalent COVID-19 boosters are limited. AimWe evaluated the long-term protection of bivalent boosters against severe COVID-19 among ≥ 65-year-olds in Finland. MethodsIn this register-based cohort analysis, we compared the risk of three severe COVID-19 outcomes among ≥ 65-year-olds who received a bivalent booster (Original/Omicron BA.1 or Original/BA.4–5; exposed group) between 1/9/2022 and 31/8/2023 to those who did not (unexposed). We included individuals vaccinated with at least two monovalent COVID-19 vaccine doses before 1/9/2022 and ≥ 3 months ago. The analysis was divided into two periods: 1/9/2022–28/2/2023 (BA.5 and BQ.1.X predominating) and 1/3/2023–31/8/2023 (XBB predominating). The hazards for the outcomes between exposed and unexposed individuals were compared with Cox regression. ResultsWe included 1,191,871 individuals. From 1/9/2022 to 28/2/2023, bivalent boosters were associated with a reduced risk of hospitalisation due to COVID-19 (hazard ratio (HR): 0.45; 95% confidence interval (CI): 0.37–0.55), death due to COVID-19 (HR: 0.49; 95% CI: 0.38–0.62), and death in which COVID-19 was a contributing factor (HR: 0.40; 95% CI: 0.31–0.51) during 14–60 days since vaccination. From 1/3/2023 to 31/8/2023, bivalent boosters were associated with lower risks of all three severe COVID-19 outcomes during 61–120 days since a bivalent booster (e.g. HR: 0.53; 95% CI: 0.39–0.71 for hospitalisation due to COVID-19); thereafter no notable risk reduction was observed. No difference was found between Original/Omicron BA.1 and Original/BA.4–5 boosters. ConclusionBivalent boosters initially reduced the risk of severe COVID-19 outcomes by ca 50% among ≥ 65-year-olds, but protection waned over time. These findings help guide vaccine development and vaccination programmes.
Læs mereStatens Serum Institut, 13.09.2024
Tilføjet 13.09.2024
En ekstra vaccination mod covid-19 giver en markant sundhedsgevinst til immunsvækkede personer, viser en ny nordisk undersøgelse, som Statens Serum Institut (SSI) har ledet.
Læs mere